Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

Vuong, Huy Gia; Nguyen, Thu Quynh; Nguyen, Hoang Cong; Nguyen, Phuoc Truong; Ho, An Thi Nhat; Hassell, Lewis

doi:10.1007/s11523-020-00745-7

Cited by 24 publications

(13 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding the cardiovascular toxicities of alectinib and crizotinib is important given the prevalent usage of alectinib for ALK-rearranged NSCLC and of crizotinib for ROS1-rearranged NSCLC (in addition to NSCLC with MET abnormalities). 13,14 Our findings of an association between both crizotinib and alectinib and conduction disease are concordant with clinical trial data. Phase 3 PROFILE 1007 and 1014 trials detected 10% incidence of sinus bradycardia and 2% of QT prolongation from crizotinib.…”

Section: Discussionsupporting

confidence: 87%

Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC

Waliany

Zhu

Wakelee

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC

Waliany

Zhu

Wakelee

et al. 2021

Journal of Thoracic Oncology

View full text Add to dashboard Cite

“…Several cases and clinical studies have reported the efficacy of crizotinib and cabozantinib in targeting MET amplification[ 12 , 13 ], exon 14 skipping[ 14 ], and certain rearrangements[ 5 - 7 , 10 ] in NSCLC patients. A recent meta-analysis analyzed six clinical trials (cohort size range: 8-69) on MET -altered NSCLC revealed an objective response rate of 40.6% (95%CI: 28.3%–53.0%) and disease control rate of 78.9% (95%CI: 70.3%–87.4%) for crizotinib, with a median progression-free survival and overall survival of 5.2 and 12.7 mo, respectively[ 15 ]. Most of these studies enrolled few MET fusion-positive patients, because they are exceedingly rare.…”

Section: Introductionmentioning

confidence: 99%

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

Liu¹,

Deng²,

Lizaso³

et al. 2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Due to the rarity of mesenchymal-epithelial transition factor ( MET ) fusions, the clinical efficacy of crizotinib has only been described in a few patients with MET fusions involving various fusion partners. Herein, we report the clinical response to crizotinib of a patient with advanced poorly differentiated non-small cell carcinoma (NSCLC) having concurrent MET fusions. CASE SUMMARY A 46-year-old woman was diagnosed with poorly differentiated NSCLC (T4N3M1). With no classic driver mutations, she was treated with two cycles of gemcitabine and cisplatin without clinical benefit. Targeted sequencing revealed the detection of two concurrent MET fusions, KIF5B-MET and novel MET-CDR2 . Crizotinib was initiated at a dose of 250 mg twice daily. Within 4 wk of crizotinib therapy, repeat computed chromatography revealed a dramatic reduction in primary and metastatic lesions, assessed as partial response. She continued to benefit from crizotinib for 3 mo until disease progression and died within 1 mo despite receiving nivolumab therapy. CONCLUSION Crizotinib sensitivity was observed in an advanced poorly differentiated NSCLC patient with concurrent MET fusions KIF5B-MET and MET-CDR2 . Crizotinib can serve as a therapeutic option for patients with MET fusions. In addition, our case also highlights the importance of comprehensive genomic profiling particularly in patients with no classic driver mutation for guiding alternative therapeutic decisions.

show abstract

“…In order to enhance the practice of evidencebased medicine, especially with the envisaged continued growth in expenditure on medicines for patients with cancer, a systematic review with meta-analysis was conducted to synthesize the scientific evidence regarding the use of crizotinib for the first-line treatment of advanced or metastatic NSCLC for patients with a fusion type rearrangement. We are aware that there have been systematic reviews comparing different ALK inhibitors for NSCLC as well as specific subtypes and safety issues [17][18][19][20][21]. However, we wanted to specifically concentrate on crizotinib due to the typically higher price of some newer agents [22,23].…”

Section: Introductionmentioning

confidence: 99%

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Cruz

Barbosa²,

Tôrres

et al. 2021

Oncol Ther

View full text Add to dashboard Cite

Introduction: Lung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2-5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment.Objective: To conduct a systematic review and meta-analysis to estimate the magnitude of the overall survival (OS) and progression-free survival (PFS) from using crizotinib as treatment compared to traditional chemotherapy to guide future decision making. Methods: PRISMA and Cochrane recommendations were followed using the findings based on studies published in the main international electronic databases. Selection criteria included the following: randomized clinical trials (RCT) or cohort studies that had assessed the efficacy and effectiveness of crizotinib as monotherapy in patients with NSCLC with ALK fusions. Results: From 2504 publications identified in the literature, only eight publications referring to seven studies met the selection criteria, with high heterogeneity identified between the studies. Overall, there was a significant gain in PFS (HR 0.38; 95% CI 0.30-0.49; p \ 0.00001); however, there was no significant gain in OS (HR 0.68; 95% CI 0.43-1.08; p = 0.10). Conclusion:The study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion, as previously reported. However, there was no increase in overall survival in patients with NSCLC with genetic alterations of ALK. This must be considered when reviewing and funding treatments for NSCLC patients with this

show abstract

Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

Cited by 24 publications

References 58 publications

Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC

Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About